Earnings summaries and quarterly performance for Picard Medical.
Executive leadership at Picard Medical.
Board of directors at Picard Medical.
Research analysts covering Picard Medical.
Recent press releases and 8-K filings for PMI.
Picard Medical, Inc. Publishes Investor Presentation Outlining Growth Strategy
PMI
Product Launch
New Projects/Investments
Guidance Update
- Picard Medical, Inc. (PMI) published an investor presentation on January 13, 2026, detailing its strategy and outlook.
- The company's subsidiary, SynCardia Systems, LLC, is a leader in the total artificial heart market, with the SynCardia Total Artificial Heart (STAH) being the only FDA-approved commercially available total artificial heart.
- PMI anticipates significant growth driven by near-, mid-, and long-term initiatives, including expected approvals for an updated BTC Label in 2Q26, MDR CE-Mark and NMPA Approval in 4Q26, and future FDA approvals for new products like Emperor in 2H28 and Unicorn in 1H28.
- As of January 11, 2026, Picard Medical, Inc. had a market capitalization of approximately $123 million.
Jan 13, 2026, 1:51 PM
Picard Medical Secures Up to $50 Million Senior Secured Debt Financing
PMI
Debt Issuance
New Projects/Investments
- Picard Medical, Inc. announced a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028, along with warrants to purchase common stock.
- An initial $15.0 million principal amount of notes was issued on December 26, 2025, with the option to fund an additional $35.0 million.
- The notes carry an annual interest rate of 0.00% and mature on December 26, 2028.
- The financing includes warrants to purchase 7,009,346 shares of the Company's common stock.
- The net proceeds from the financing are intended for working capital and general corporate purposes, and the company must maintain a minimum of $4,000,000 in cash while the notes are outstanding.
Dec 30, 2025, 11:00 AM
Picard Medical, Inc. Presents Data on New Fully Implantable Artificial Heart
PMI
Product Launch
New Projects/Investments
- On December 4, 2025, Picard Medical, Inc. presented in vitro and acute in vivo data on its new Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support.
- The Emperor TAH is a fully implantable, driver-less evolution of the existing SynCardia Total Artificial Heart (STAH), which is FDA-approved and has been implanted in over 2,100 patients.
- This new device replaces the STAH's external pneumatic driver with a compact electromechanical system, featuring internal batteries and a transcutaneous energy transfer system, thereby eliminating the need for a transdermal driveline.
- Testing demonstrated that the Emperor TAH maintains equivalent physiological performance, including autoregulation and afterload independence, compared to the pneumatic STAH.
- The device was successfully implanted in three porcine models, showing stable circulatory support and efficient energy use without technical issues.
Dec 4, 2025, 1:00 PM
Picard Medical's SynCardia Completes First In Vivo Implantations of Emperor Total Artificial Heart
PMI
Product Launch
New Projects/Investments
- Picard Medical, Inc. (PMI) announced on November 19, 2025, that its wholly owned subsidiary, SynCardia Systems LLC, successfully completed the first in vivo implantations of the next-generation Emperor Total Artificial Heart.
- The Emperor Total Artificial Heart (TAH) was successfully implanted in three pre-clinical models, demonstrating full and stable blood circulation, efficient energy use, and operation without technical problems, closely mirroring natural heart function.
- This achievement marks a major milestone in advancing a driverless total artificial heart, strengthening Picard Medical's leadership in the technology and validating the potential of the Emperor platform.
Nov 19, 2025, 9:15 PM
Picard Medical Stockholders Approve Amended Equity Incentive Plan
PMI
Executive Compensation
Proxy Vote Outcomes
- On October 10, 2025, Picard Medical, Inc. stockholders approved an amendment to the company's 2021 Equity Incentive Plan at a special meeting.
- The amendment increases the aggregate number of shares of Common Stock available under the plan to a total of 18,000,000 shares.
- Additionally, the amendment includes warrants as a type of award issuable under the Amended Incentive Plan.
- The proposal received strong stockholder support, with 46,424,590 votes for the amendment, compared to 7,727 against and 7,945,013 abstentions.
Oct 14, 2025, 10:02 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more